Advertisement
U.S. markets closed
S&P Futures
5,908.75 +2.75 (+0.05%) Dow Futures
43,550.00 +32.00 (+0.07%) Nasdaq Futures
20,490.25 +6.75 (+0.03%) Russell 2000 Futures
2,294.30 +3.10 (+0.14%) Crude Oil
69.48 +0.26 (+0.38%) Gold
2,745.00 +15.00 (+0.55%)
Biotest Aktiengesellschaft (BIO3.DE)
XETRA - XETRA Delayed Price. Currency in EUR
Follow
At close: 05:36PM CEST
| Previous Close | 27.70 |
| Open | 27.70 |
| Bid | 0.00 x 53100 |
| Ask | 0.00 x 20000 |
| Day's Range | 27.70 - 27.70 |
| 52 Week Range | 22.80 - 31.80 |
| Volume | |
| Avg. Volume | 656 |
| Market Cap | 1.375B |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | 6.67 |
| EPS (TTM) | 4.15 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | 0.04 (0.14%) |
| Ex-Dividend Date | May 08, 2024 |
| 1y Target Est | N/A |
- GuruFocus.com
Biotest AG (WBO:BIO3) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Biotest AG reports a 35% revenue increase and FDA approval for Yimmugo, setting the stage for U.S. market entry in 2025.
Pharmaceutical TechnologyBiotest wins FDA approval for plasma protein therapy
The US Food and Drug Administration (FDA) approved Biotest’s Yimmugo for the treatment of primary antibody deficiencies.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.